Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. This technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for many patients.
Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. The company believes pharmacological chaperone technology has broad applicability and expects to expand the portfolio to include other diseases of neurodegeneration, metabolic diseases, and oncology. Founded in 2002, Amicus has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records of developing and bringing to market drugs for genetic diseases. Amicus continues to develop its pharmacological chaperone technology and has built a significant intellectual property portfolio along with its robust clinical and preclinical pipeline.
Amicus has a fast-paced, high-energy, entrepreneurial team environment where employees are encouraged to be innovative and resourceful. Amicus seeks high-caliber, talented individuals with a passion to succeed.
Company Growth (employees)
Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury Township, US
Key People at Amicus Therapeutics
William D. Chip Baird
Chief Financial Officer
Bradley L Campbe
Chief Operating Officer
Jeffrey P Castelli
Vice President
Enrique Diloné
Vice President
Jay A Barth
Chief Medical Officer
Hung Do
Senior Vice President
Amicus Therapeutics Office Locations
Amicus Therapeutics has offices in Cranbury Township, Denham, Munich, Puteaux and in 1 other location
Cranbury Township, US (HQ)
1 Cedar Brook Drive
Puteaux, FR
Tour Défense 2000
Amicus Therapeutics Data and Metrics
Amicus Therapeutics Financial Metrics
Amicus Therapeutics's revenue was reported to be $5 m in FY, 2016
USD
Net income (Q1, 2017) | (55 m) |
EBIT (Q1, 2017) | (52 m) |
Market capitalization (25-Jul-2017) | 2 b |
Cash (31-Mar-2017) | 44.8 m |
Amicus Therapeutics's current market capitalization is $2 b.
- Source: SEC Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 122.2 m | 1.2 m | 5 m | |
Revenue growth, % | (99%) | (100%) | ||
Cost of goods sold | 833 k | |||
Gross profit | 4.1 m | |||
Gross profit Margin, % | 83% | |||
R&D expense | 104.8 m | |||
General and administrative expense | 71.2 m | |||
Operating expense total | 527.8 m | 69.9 m | 130.4 m | 186 m |
EBIT | (405.6 m) | (68.7 m) | (130.4 m) | (181.9 m) |
EBIT margin, % | (332%) | (5613%) | (3669%) | |
Interest expense | 46 k | 1.5 m | 1.6 m | 5.4 m |
Interest income | 174 k | 223 k | 929 k | 1.6 m |
Income tax expense | 3.5 m | 1.1 m | 1.1 m | 3.7 m |
Net Income | (378.5 m) | (68.9 m) | (132.1 m) | (200 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 475 k | 293 k | 456 k | 475 k | 293 k | ||||
Cost of goods sold | 344 k | 775 k | |||||||
R&D expense | 10 m | 12 m | 16.1 m | 17.2 m | 21 m | 23.4 m | 18.3 m | 32.5 m | 30.9 m |
General and administrative expense | 4.8 m | 5.3 m | 6.4 m | 8.3 m | 15.4 m | 15.7 m | 19.3 m | 17.5 m | 19.1 m |
Operating expense total | 14.7 m | 17.3 m | 22.5 m | 25.5 m | 36.3 m | 39.1 m | 37.6 m | 49.9 m | 50 m |
EBIT | (14.3 m) | (16.8 m) | (24.1 m) | (26.9 m) | (38 m) | (43 m) | (48.5 m) | (44.9 m) | (52 m) |
EBIT margin, % | (3003%) | (5739%) | (5276%) | (5672%) | (12985%) | ||||
Interest expense | (374 k) | (377 k) | (372 k) | (338 k) | (17 k) | (945 k) | (1.1 m) | (1.5 m) | (4.3 m) |
Interest income | 36 k | 55 k | 171 k | 158 k | 316 k | 307 k | 331 k | 460 k | 759 k |
Income tax expense | 453 k | 253 k | (56 k) | ||||||
Net Income | (30.6 m) | (47.7 m) | (24.3 m) | (51.4 m) | (89.2 m) | (43.7 m) | (94.7 m) | (141.4 m) | (55 m) |
- Source: SEC Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 43.6 m | 24.1 m | 69.5 m | 187 m |
Accounts Receivable | 1.3 m | |||
Inventories | 5.5 m | 2.9 m | 2.6 m | 3.4 m |
Current Assets | 88.3 m | 154.6 m | 216.6 m | 340.1 m |
Goodwill | 11.6 m | 11.6 m | 197.8 m | 197.8 m |
Total Assets | 127.6 m | 210 m | 908.4 m | 1 b |
Accounts Payable | 10.2 m | 16.3 m | 32.2 m | 185.5 m |
Current Liabilities | 10.5 m | 20.2 m | 73.6 m | 111 m |
Additional Paid-in Capital | 423.6 m | 568.7 m | 917.5 m | 1.1 b |
Retained Earnings | (447.4 m) | (579.6 m) | (779.6 m) | |
Total Equity | 45.8 m | 122.2 m | 347.8 m | 360.2 m |
Financial Leverage | 2.8 x | 1.7 x | 2.6 x | 2.9 x |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 41.9 m | 19.7 m | 28.8 m | 249 m | 19.4 m | 23.5 m | 63.7 m | 33.1 m | 44.8 m |
Accounts Receivable | 864 k | 1.9 m | |||||||
Inventories | 194 k | 3.3 m | 3.7 m | ||||||
Current Assets | 79.4 m | 87.2 m | 151.3 m | 365 m | 240.1 m | 168.5 m | 217.7 m | 221.7 m | 296.2 m |
Goodwill | 11.6 m | 11.6 m | 11.6 m | 11.6 m | 207.6 m | 197.8 m | 197.8 m | 197.8 m | 197.8 m |
Total Assets | 118 m | 125.5 m | 192.6 m | 403.9 m | 986.7 m | 862.9 m | 914 m | 918.2 m | 993.4 m |
Accounts Payable | 9.9 m | 11.3 m | 15.8 m | 16.9 m | 30.6 m | 22.5 m | 23.8 m | 29 m | |
Current Liabilities | 11.2 m | 13.8 m | 21 m | 16.9 m | 35.9 m | 64.4 m | 80.5 m | 85.6 m | 109.6 m |
Additional Paid-in Capital | 444.6 m | 468.7 m | 574.8 m | 826.6 m | 914.3 m | 921.2 m | 990 m | 1 b | 1.1 b |
Retained Earnings | (409.1 m) | (426.2 m) | (471.7 m) | (498.9 m) | (536.7 m) | (623.3 m) | (674.3 m) | (721 m) | (834.6 m) |
Total Equity | 36.3 m | 43.3 m | 104 m | 328.9 m | 378.8 m | 311.6 m | 334.2 m | 336.6 m | 310.8 m |
Financial Leverage | 3.2 x | 2.9 x | 1.9 x | 1.2 x | 2.6 x | 2.8 x | 2.7 x | 2.7 x | 3.2 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (59.6 m) | (68.9 m) | (132.1 m) | (200 m) |
Depreciation and Amortization | 1.7 m | 1.5 m | 1.8 m | 3.2 m |
Accounts Receivable | (1.4 m) | |||
Inventories | (3.2 m) | 2.3 m | 308 k | (3.7 m) |
Accounts Payable | 6.2 m | 15.5 m | 7.1 m | |
Cash From Operating Activities | (45.8 m) | (51.7 m) | (100.1 m) | (150.5 m) |
Purchases of PP&E | (695 k) | (238 k) | (4.8 m) | (6 m) |
Cash From Investing Activities | (145.3 m) | (4.5 m) | ||
Cash From Financing Activities | 139.2 m | 290.9 m | 272.7 m | |
Interest Paid | 30 k | 1.2 m | 605 k | 3 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (30.6 m) | (47.7 m) | (24.3 m) | (51.4 m) | (89.2 m) | (43.7 m) | (94.7 m) | (141.4 m) | (55 m) |
Depreciation and Amortization | 808 k | 1.2 m | 508 k | 861 k | 1.3 m | 673 k | 1.4 m | 2.3 m | 823 k |
Accounts Receivable | (863 k) | (512 k) | |||||||
Inventories | (207 k) | (3.5 m) | (243 k) | ||||||
Accounts Payable | (155 k) | 1.2 m | (551 k) | 459 k | 14.1 m | (9.8 m) | (8.2 m) | (2.9 m) | (1.3 m) |
Cash From Operating Activities | (22 m) | (37.2 m) | (21 m) | (43.6 m) | (64.6 m) | (44.9 m) | (77.7 m) | (118.5 m) | (49.8 m) |
Purchases of PP&E | (132 k) | (192 k) | (753 k) | (1.4 m) | (2.2 m) | (2.9 m) | (4.6 m) | (5.5 m) | (732 k) |
Cash From Investing Activities | 2.1 m | (27.3 m) | 31.3 m | (230.7 m) | (39.9 m) | (92.4 m) | |||
Cash From Financing Activities | 18.2 m | 40.5 m | 4.1 m | 237.2 m | 290.7 m | 82.8 m | 122.4 m | (95 k) | |
Interest Paid | 537 k | 864 k | 209 k | 605 k | 605 k | 209 k | 276 k | 284 k | 12 k |
| Y, 2017 | |
|---|---|
Financial Leverage | 3.2 x |
